<DOC>
	<DOCNO>NCT00456235</DOCNO>
	<brief_summary>The aim project determine whether , liver transplant patient side effect due ICN , use MMF monotherapy optimise dose adjustment base area curve ( AUC ) mycophenolic acid ( MPA ) . It involve multicentre phase IV trial direct individual benefit . A population 130 liver transplant patient 2 10 year post-transplant , show significant clinical ICN side effect give bitherapy ICN +MMF include randomised 1:1 two arm : - Arm 1 : progressive interruption ICN obtain AUC MPA 50 mg.h/l , follow MMF monotherapy dose adjustment base AUC MPA , - Arm 2 : continuation ICN+MMF bitherapy without MMF therapeutic drug monitoring . The main judgement criterion incidence acute rejection 2 group 6 month . The secondary judgment criterion evaluation benefit stop ICN side effect cause drug .</brief_summary>
	<brief_title>Reduction Risk Rejection Mycophenolate Mofetil Dose Adjustment Liver Transplant Patients With Side Effects Caused Calcineurine Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient first liver transplantion retransplantation since 6 month : posttransplant lapse time 2 10 year show one follow adverse effect ICN : Renal insufficiency define creatinine clearance &lt; 50ml/mn ( calculate estimate accord Cockcroft formula ) Arterial hypertension control antihypertensive bitherapy Diabetes mellitus ( fast glycaemia &gt; 7.0mmol/l ) , whether treat Neuromuscular toxicity Immunosuppression cyclosporine tacrolimus MMF Hepatic biopsy perform within 6 month precede inclusion patient posttransplant period &lt; 5 year 12 month precede inclusion patient post transplant period &gt; 5 year . Acute rejection within 6 month precede screen Previous history corticoresistant rejection Chronic rejection Significant ductopenia ( absence interlobule biliary canal 30 % portal tract ) prescreening biopsy . Existence pretransplantation diabetes mellitus . Liver transplantation autoimmune hepatitis primary sclerosing cholangitis Patients transplant viral C cirrhosis reinfection lesion transplant organ , render treatment ribarivine + interferon conceivable year follow inclusion . Counterindications MMF ( anaemia , leucopenia ) Immunosuppression sirolimus , everolimus , azathioprine corticoid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>